A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Mercaptamine (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARE-CF-1; CARE-CF2
- Sponsors NovaBiotics
- 29 Dec 2020 According to a NovaBiotics media release, results from this study were published in the PLOS ONE Journal.
- 04 Jun 2019 According to a NovaBiotics media release, data from this trial will be presented at the European CF Society Conference (ECFS) (June 2019).
- 17 Oct 2018 According to a NovaBiotics media release, data from this trial will be presented at the North American Cystic Fibrosis Conference (NACFC) (18th - 20th October 2018).